Mustafa Kemal Çelen, Celal Ayaz, Habibe Çolak, Recep Tekin

Comparison of lamivudine - α-interferon combination and α-interferon

Anahtar Kelimeler:

Chronic hepatitis B, HBeAg negative, combination therapy, α-interferon, lamivudine

Comparison of lamivudine - α-interferon combination and α-interferon alone treatments in adult patients with naive HBeAg negative hepatitis B

Objectives: This study aimed to compare the efficacy of the α-interferon treatment with α-interferon plus lamivudine for cases of chronic hepatitis B. Materials and methods: Sixty-one HBeAg negative naive chronic hepatitis B patients were randomly evaluated in two groups prospectively. In group 1, 30 patients were simultaneously given α-interferon 2a 9 MU, 3 days a week by s.c. injection plus lamivudine 100 mg a day for 12 months. In group II, there were 31 patients who only was received the same dosage of α-interferon and no lamivudine over the same period of time. Results: In group 1 the initial mean value of alanine aminotransferase (ALT) was 144±59 IU/L and decreased to 38.8±19.3 IU/L; in group II, initial mean values of ALT was 141±52 IU/L and decreased to 53.2±14.7 IU/L at the end of 12th month of the therapy (P<0.05). Hepatitis B virus DNA (HBV-DNA) clearance was obtained in 13 of 30 patients (43.3%) in group I patients and 15 of 31 (48.4%) in group II at the end of the therapy (p=0.692). The number of patients with complete response was found to be 14 out of 30 (48.4%) in group 1 and 15 out of 31 cases (46.7%) in group II, six months after the end of the therapy (P=0.893). Conclusion: α-interferon and lamivudine combination therapy had a more beneficial effect than α-interferon monotherapy in normalization of ALT and clearance of HBV-DNA; however, the complete response rate at 6 months after the end of the therapy was not statistically significantly different between both groups.

PDF

___

Lee WM. Hepatitis B virus infection. N Eng J Med 1997; 337:1733-1745.

WHO. World Health Report 1996: fighting disease, fostering development, Geneva: World Health Organization, 1996.

Yao F, Gish RG. Treatment of chronic hepatitis B: new antiviral therapies. Curr. Gastroenterol Rep 1999; 1: 20-26.

Gurkan F, Kocak N, Ozen H, Yuce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr. Infect Dis J 2000; 19: 52-56.

Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003;36:1516-1522.

Nevens F, Main J. Honkoop P et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997:113;1258-1263.

Dikici B, Bosnak M, Bosnak V et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and α-interferon combination and α-interferon alone. Pediatrics Int 2002: 44; 517-521.

Thakur V, Sarin SK, Rehman S et al. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol 2005;24:12-15.

Mutimer D, Dowling D, Cane P et al. Additive antiviral effects of lamivudine and α-interferon in chronic hepatitis B infection. Antivir Ther 2000; 5: 273-277.

Wong DKH, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. Ann Intern Med 1993; 119:312 323.

Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-1325.

Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256 1263.

Lai CL, Chien RN, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168.

Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigennegative chronic hepatitis B. Hepatology 2001; 34: 617-624.

Knodell RG, Ishak KG, Black WC et al. Formulation and applicationof a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.

Ruiz Moreno M. Chronic hepatitis B in children: natural history and treatment. J Hepatol 1993; 17: 64 66.

Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347 356.

Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, Jin LJ, Yang ZJ, Xu YP. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigennegative Chinese patients and its suppression of lamivudineresistant mutations. J Antimicrob Chemother 2006; 58: 10311035.

Pessoa MG, Wright TL. Update on clinical trials in the treatment of hepatitis B. J Gastroenterol Hepatol 1999; 14: S611.

Regev A, Schiff ER. Drug therapy for hepatitis B. Adv Intern Med 2001; 46: 107-135.

Seehofer D, Rayes N, Berg T et al. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. Transplantation 2000; 69: 1739-1742.

Terrault NA. Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection? Hepatology 2000; 32:675-677. 23. Lok AS, Heathcote J, Hoofnagle J. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120:1828-1853. 24. Janssen HLA, Gerken G, Carreno V, et al. Interferon alpha for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology 1999; 30:238-243. 25. Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect 2005;38:262-266. 26. Economou M, Manolakopoulos S, Trikalinos TA, Filis S, Bethanis S, Tzourmakliotis D, Avgerinos A, Raptis S, Tsianos EV. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005;11:5882-5887.